IP Library Granted Patent US 12,049,443
Granted Patent B2
US 12,049,443 · App. 17/312,374 · Granted Jul 30, 2024

Synthesis of conjugated diene pheromones and related compounds

Inventors: Keith M. Wampler (Santa Monica, CA); Choon Woo Lee (Santa Monica, CA); David Rozzell (Santa Monica, CA)
Assignee: PROVIVI, INC.
C07C67/343B01J31/2442C07C45/68B01J2531/821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,049,443
App. No.
17/312,374
Granted
Jul 30, 2024
Kind
B2
Abstract

Methods for preparing conjugated dienes are described. An α,β-unsaturated E olefin intermediate may be prepared via cross-metathesis using a catalyst comprising a transition metal (e.g., ruthenium), a first carbene ligand (e.g., a substituted indenylidene) and an N-heterocyclic carbene ligand (e.g., an imidazolidinylidene). The catalyst further includes a phenylphosphine ligand, a tri(isopropoxy)phosphine ligand, a dimethylsulfoxide ligand, an acetonitrile ligand, or a pyridine ligand. Following the cross metathesis-step, the α,β-unsaturated aldehyde intermediate may be converted to the conjugated diene product via reaction with a phosphonium ylide. Products obtained via the methods of the disclosure include (7E,9Z)-dodeca-7,9-dien-1-yl acetate, a pheromone produced by Lobesia botrana (European grapevine moth), and other insect pheromones.

Claims (45)

1. A method for preparing a conjugated diene according to Formula I:

the method comprising:

(i) forming a reaction mixture comprising:

an olefin according to Formula V:

 a crotonaldehyde, and

a metathesis catalyst according to Formula VI:

(ii) maintaining the reaction mixture under conditions sufficient to form a metathesis product according to Formula III:

 and

(iii) combining the metathesis product according to Formula III with a phosphonium ylide according to Formula II:

under conditions sufficient to form the conjugated diene according to Formula I, wherein:

R 1 is —OR 1a , —C(O)OR 1b , or —C(O)H,

R 1a is C 1-6 acyl or H,

R 1b is H or C 1-6 alkyl,

R 2 is C 3-12 alkyl or C 1-2 alkyl,

R 3a and R 3b are independently H or C 1-6 alkyl,

each R 5 is independently optionally substituted C 6 -C 10 aryl,

subscript x is an integer ranging from 6 to 12 or an integer ranging from 1 to 5,

R 6 and R 7 , together with the carbon atom to which they are attached, form a first carbene ligand,

R 8 and R 9 are independently anionic ligands,

L 1 is a N-heterocyclic carbene ligand, and

L 2 is a phenylphosphine ligand, a tri(isopropoxy)phosphine ligand, a dimethylsulfoxide ligand, an acetonitrile ligand, or a pyridine ligand.

2. The method of claim 1 , wherein the conjugated diene is an E,Z-diene.

3. The method claim 1 , wherein the first carbene ligand is optionally substituted indenylidene, optionally substituted alkylidene, optionally substituted benzylidene, optionally substituted vinylidene, or optionally substituted allenylidene.

4. The method of claim 1 , wherein R 6 and R 7 , together with the carbon atom to which they are attached, form 3-phenyl-1H-inden-1-ylidene, benzylidene, or 3-methylbut-2-en-1-ylidene.

5. The method of claim 4 , wherein R 6 and R 7 , together with the carbon atom to which they are attached, form 3-phenyl-1H-inden-1-ylidene.

6. The method of claim 1 , wherein L 1 is optionally substituted imidazolidin-2-ylidene.

7. The method of claim 1 , wherein the metathesis catalyst is selected from:

wherein “Ph” represents phenyl, “iPr” represents isopropyl, and DMSO represents dimethylsulfoxide.

8. The method of claim 1 , wherein the amount of the metathesis catalyst in the reaction mixture is less than 0.05 mol % with respect to the total amount of olefin according to Formula V and the crotonaldehyde.

9. The method of claim 1 , wherein the molar ratio of the crotonaldehyde to the olefin according to Formula V ranges from about 1.5:1 to about 3:1.

10. The method of claim 1 , wherein the metathesis product according to Formula III of step (ii) is not purified prior to step (iii).

11. The method of claim 1 , wherein the phosphonium ylide according to Formula II is formed by reacting a base with an alkylphosphonium halide according to Formula IIa

wherein X is halogen.

12. The method of claim 11 , wherein the base is potassium tert-butoxide.

13. The method of claim 1 , wherein the conjugated diene is selected from the group consisting of (7E,9Z)-dodeca-7,9-dien-1-yl acetate, (3E,5Z)-dodeca-3,5-dien-1-yl acetate, (3E,5Z)-dodeca-3,5-dien-1-yl acetate, (5E,7Z)-dodeca-5,7-dien-1-yl acetate, (8E,10Z)-dodeca-8,10-dien-1-yl acetate, (5E,7Z)-dodeca-5,7-dien-1-ol, (5E,7Z)-dodeca-5,7-dienal, (7E,9Z)-dodeca-7,9-dien-1-ol, (7E,9Z)-dodeca-7,9-dienal, (8E,10Z)-dodeca-8,10-dien-1-ol, (8E,10Z)-dodeca-8,10-dienal, (2E,4Z)-hepta-2,4-dien-1-ol, (2E,4Z)-hepta-2,4-dienal, (2E,4Z)-octa-2,4-dienal, (4E,6Z)-octa-4,6-dienoic acid, (2E,4Z)-deca-2,4-dienal, ethyl (2E,4Z)-deca-2,4-dienoate, (10E,12Z)-tetradeca-10,12-dien-1-yl acetate, (3E,5Z)-tetradeca-3,5-dienoic acid, (3E,5Z)-tetradeca-3,5-dien-1-yl acetate, (8E,10Z)-tetradeca-8,10-dienal, (8E,10Z)-tetradeca-8,10-dien-1-yl acetate, (9E,11Z)-tetradeca-9,11-dien-1-yl acetate, (6E,8Z)-pentadeca-6,8-dienal, (8E,10Z)-pentadeca-8,10-dien-1-ol, (8E,10Z)-pentadeca-8,10-dien-1-yl acetate, (9E,11Z)-pentadeca-9,11-dienal, (10E,12Z)-hexadeca-10,12-dien-1-ol, (10E,12Z)-hexadeca-10,12-dienal, (10E,12Z)-hexadeca-10,12-dien-1-yl acetate, (11E,13Z)-hexadeca-11,13-dien-1-ol, (11E,13Z)-hexadeca-11,13-dienal, (11E,13Z)-hexadeca-11,13-dien-1-yl acetate, (9E,11Z)-hexadeca-9,11-dienal, and (9E,11Z)-hexadeca-9,11-dien-1-yl acetate.

14. The method of claim 1 , wherein the conjugated diene is (7E,9Z)-dodeca-7,9-dien-1-yl acetate.

15. The method of claim 1 , wherein the metathesis product according to Formula III formed during step (ii) has a molar ratio of E olefin to Z olefin greater than 20:1.

16. The method of claim 1 , wherein the conjugated diene according to Formula I formed during step (iii) has a molar ratio of Z olefin to E olefin greater than 8:1.

17. The method of claim 1 , wherein:

the olefin according to Formula Vis oct-7-en-1-yl acetate,

the metathesis product according to Formula III is E-9-oxonon-7-en-1-yl acetate,

the phosphonium ylide according to Formula II is triphenyl(propylidene)-25-phosphane, and

the conjugated diene is E,Z-dodeca-7,9-dien-1-yl acetate.

18. The method of claim 17 , wherein the metathesis catalyst is 1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(3-phenyl-1H-inden-1-ylidene)(triphenylphosphine)ruthenium (II):

19. The method of claim 1 , wherein the phenylphosphine ligand is a triphenylphosphine.

Assignments (2)
SECURITY INTEREST Recorded Aug 24, 2023
From: PROVIVI, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064697/0700 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2021
From: WAMPLER, KEITH M.; LEE, CHOON WOO; ROZZELL, DAVID
To: PROVIVI, INC.
Reel/Frame 057903/0468 →
Continuity (2)
Provisional Application 62777680 · Dec 10, 2018
Related Publication 20220017449A1 · Jan 20, 2022